摘要
Due to the rapid spread of coronavirus disease 2019(COVID-19),there is an urgent requirement for the development of additional diagnostic tools for further analysis of the disease.The isolated nanobody Nb11-59 binds to the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)reeptor-binding domain[RBD]with high afinity to neutralize the virus and block the angiotensin-converting enzyme 2-(ACE2-)RBD interaction.Here,we introduce a novel nanobody-based radiotracer named^(68)Ga-Nb1159.The radiotracer retained high affinity for the RBD and showed reliable radiochemical characteristics both in vitro and in vivo.Predinical positron emission tomography(PET)studies of Ga-Nb1159 in mice revealed is rapid dearance from circulation and robust uptake into the renal and urinary systems.Fortunately,^(68)Ga-Nb1159 could speifcally reveal the distribution of the RBD in mice.This sudy also helped to evaluate the pharmacodynamic efects of the neutralizing nanobody.Moreover,^(68)Ga-Nb1159 may be a promising l0ol lo explore the distribution of the RBD and improve the understanding of the virus.In particular,this study identified a novel molecular radioagent and established a reliable evaluation method for speifially investigating the RBD through noninvasive and visual PET technology.
出处
《Research》
EI
CAS
CSCD
2022年第2期85-98,共14页
研究（英文）
基金
supported by the National Natural Science Foundation of China(Nos.82171973 and 82171980)
Peking University Health Science Center discipline construction funding(B00078)
This study was also supported by the third foster plan in 2019“Molecular Imaging Probe Preparation and Characterization of Key Technologies and Equipment"(#ZDKJ20190305003)for the development of key technologies and equipment in major science and technology infrastructure in Shenzhen and The Pilot Project(4th Round)to Reform Public Development of Beijing Municipal Medical Research Institute(2021-1)
We thank for the useful discussion Prof.Daniel LJ.Thorek and Dr.Hanwen Zhang from Washington University,and Prof.Sanjay K.Jain from Johns Hopkins University School of Medicine.
